Skip Navigation



NDT Advance Access published online on July 16, 2008
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfn376
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
23/10/3041    most recent
gfn376v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Axelsson, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Axelsson, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


The emerging biology of adipose tissue in chronic kidney disease: from fat to facts

Jonas Axelsson1

1 Divisions of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska institutet, Stockholm, Sweden

Correspondence and offprint requests to: Jonas Axelsson, Department of Renal Medicine, K56, Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden. Tel: +46-8-5858-3981; Fax: +46-8-5858-3925; E-mail: jonas.axelsson@ki.se

Keywords: Metabolism; insulin resistance; renal disease; cytokine; adipokine

The first 150 words of the full text of this article appear below.



   Introduction
 

"No diet will remove all the fat from your body because the brain is entirely fat. Without a brain, you might look good, but all you could do is run for public office."

George Bernard Shaw

Regardless of the implications, the incidence of obesity is increasing worldwide [1] and along with it the proportion of the population subject to hypertension [1] or type-2 diabetes mellitus [1]. Furthermore, the metabolic syndrome is an important risk factor for proteinuria and chronic kidney disease (CKD) independently of diabetes and hypertension [2]. For the nephrologist, this has resulted in both an increased influx of patients with CKD [2] and a larger and more obese end-stage renal disease (ESRD) population [3]. However, despite the generally reduced lifespan of obese patients not suffering from CKD [4], epidemiological studies of the impact of . . . [Full Text of this Article]



   Is uraemic fat different?
 


   Insulin resistance and uraemic dysmetabolism
 


   Adipose tissue as the largest endocrine gland in the body
 


   Adipokines as uraemic toxins mediating anorexia
 


   Fat as a source of inflammation in CKD patients
 


   Fat, bone and hypertension?
 


   Conclusion
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
Q. G. Zhou, M. Zhou, F. F. Hou, and X. Peng
Asymmetrical dimethylarginine triggers lipolysis and inflammatory response via induction of endoplasmic reticulum stress in cultured adipocytes
Am J Physiol Endocrinol Metab, April 1, 2009; 296(4): E869 - E878.
[Abstract] [Full Text] [PDF]